CDK12 ligand-3

CDK12 ligand-3 (ZZ3) (1-10000 nM) potently induces CDK12/Cyclin K-DDB1 ternary complex formation in a cell-free TR-FRET assay with an EC₅₀ of 26 nM^[1].
CDK12 ligand-3 (10-10000 nM; 6 h) potently degrades CDK12 in HEK293T cells via a DDB1- and ubiquitin-proteasome system-dependent mechanism, with a DC₅₀ of 35 nM after 6 h treatment^[1].
CDK12 ligand-3 (10-10000 nM; 6 h) potently degrades CDK13 in HEK293T cells with a DC₅₀ of 57 nM after 6 h treatment^[1].
CDK12 ligand-3 (0.01-10 μM; 6 h) induces dose-dependent degradation of CDK12, CDK13, and Cyclin K, and inhibits RNA polymerase II phosphorylation in Jurkat cells after 6 h treatment, with complete cyclin K depletion at 1 μM after 0.5 h^[1].
CDK12 ligand-3 (100 nM; 3 h) selectively degrades CDK12, CDK13, and Cyclin K in Jurkat cells^[1].
CDK12 ligand-3 (10-10000 nM; 72 h) potently inhibits Jurkat cell proliferation with an IC₅₀ of 22 nM after 72 h treatment, and this activity is dependent on the ubiquitin-proteasome system^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.